The Treatment with Mycophenolate Mofetil of Corticoresistent Nephrotic Syndrome by Idiopathic Focal Segmental Glomerulosclerosis: Analysis of Twenty Cases

1. D’Agati VD, et al: Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2013; 43: 368–382.10.1053/j.ajkd.2003.10.024Search in Google Scholar

2. Parsa A, et al: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183–2196.10.1056/NEJMoa1310345396902224206458Search in Google Scholar

3. Deegens JKJ: Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int 2011; 80: 798–01.10.1038/ki.2011.19121960168Search in Google Scholar

4. Alfonso Segarra Medrano et al: Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors. Nefrologia 2013; 33 (4): 443–622.Search in Google Scholar

5. Cattran, D.C, et al: Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405–411.10.5414/CNP62405Search in Google Scholar

6. Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80: 868.10.1038/ki.2011.195330682421734640Search in Google Scholar

7. Fernandez-Juarez G, et al: Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis.Clin Kidney J 2016; 9: 381–6.10.1093/ckj/sfw028488692027274821Search in Google Scholar

8. Morath C, Zeier M: Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003; 41: 465–9.10.5414/CPP4146514703952Search in Google Scholar

9. Penny MJ, et al: Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998; 12: 2272–82.10.1681/ASN.V9122272Search in Google Scholar

10. Wu Y, et al: Shen Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. J.Citokine 2008; 44: 85–91.10.1016/j.cyto.2008.06.015Search in Google Scholar

11. Yang CW, et al: Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 2002; 62: 20–30.10.1046/j.1523-1755.2002.00400.x12081560Search in Google Scholar

12. Morath C, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant 2005; 20 S: 25–9.10.1111/j.1399-0012.2006.00597.x17100698Search in Google Scholar

13. Li Z, Duan C, et al: Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25: 883–888.10.1007/s00467-009-1375-719953275Search in Google Scholar

14. Beer A, et al: Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades. Biomed Res Int 216; 4192578.Search in Google Scholar